Next

GRAPHICS

UTILITY OF AN ORAL PRESENTATION OF hCG (human Choriogonadotropin) FOR THE MANAGEMENT OF OBESITY. A DOUBLE-BLIND STUDY (I)

Figure 1 (A,B and C).:Body weight and bioelectrical impedance records.


During five weeks of hypocaloric diet subjects enrolled in the clinical trial were simultaneously administered a daily dose of 250 UI hCG (group G1, N=36), or 500 UI (group G2, N=8).

A third group (Placebo) received an equivalent volume of saline solution (group P, N=26). Data was obtained at the beginning and weekly during the trial period (records 0 to 5) for Body Weight (panel A) and four bioelectrical impedance assessments (here it is only displayed details from Fat and Lean weights on panels B and C, respectively).
Data are expressed in kg, mean ± SD (bars at top).

Results were submitted a priori to MANOVA analysis.

When multivariate and univariate analyses were performed taking exclusively data from weeks 2 to 5, differences between groups were strongly attenuated (see details in the text). The asterisks mark statistically significant differences between weekly records (weeks 1 to 5), and the corresponding basal values determined in week 0 (analyzed a posteriori by Scheffé F test).

* p<0.05, ** p<0.0002, *** p<0.0005

figure1.gif (9169 bytes)

(Click to enlarge)

figure2.gif (7711 bytes)

(Click to enlarge)

figure3.gif (8013 bytes)

(Click to enlarge)

The hCG and obesity  Research Clinic
Director: Dr. Daniel Belluscio
Phone and Fax+54-11-4804 97 84
Phone+54-11-4807 18 83

Proceedings of the First International Workshop on hCG and obesity
(click here)


 

 




Copyright © Dr. Daniel Belluscio 1992-2009. All rights reserved



Supervised the translation and spelling of this website

15/08/2009